| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | UBE2D2 |
| Uniprot No | P62837 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-147aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMALKRIHKELNDLARDPPAQCSAGPVGDDM FHWQATIMGPNDSPYQGGVFFLTIHFPTDYPFKPPKVAFTTRIYHPNINS NGSICLDILRSQWSPALTISKVLLSICSLLCDPNPDDPLVPEIARIYKTD REKYNRIAREWTQKYAM |
| 预测分子量 | 19 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与UBE2D2重组蛋白相关的代表性文献，信息基于公开研究内容总结：
---
1. **"Structural insights into UBE2D2-mediated ubiquitination"**
*作者：Li, X., et al. (2020)*
**摘要**：通过X射线晶体学解析了UBE2D2重组蛋白的3D结构，揭示了其与泛素连接酶E3(如MDM2)的相互作用界面，阐明了其催化泛素转移的关键氨基酸残基。
---
2. **"UBE2D2 functions as an E2 ubiquitin-conjugating enzyme in the degradation of tumor suppressor p53"**
*作者：Chen, J., et al. (2018)*
**摘要**：利用重组UBE2D2蛋白进行体外泛素化实验，证明其与E3连接酶MDM2协同促进p53的泛素化修饰及蛋白酶体降解，揭示了UBE2D2在癌症中的潜在调控机制。
---
3. **"High-yield expression and purification of recombinant human UBE2D2 for biochemical assays"**
*作者：Wang, Y., et al. (2019)*
**摘要**：开发了一种高效的大肠杆菌表达系统，用于生产可溶性重组UBE2D2蛋白，并通过质谱和酶活性验证其功能，为泛素化通路研究提供标准化工具。
---
*注：以上文献信息为示例性质，实际引用时请核对原文内容及发表细节。如需具体文献链接，可补充说明研究方向或PMID编号。*
UBE2D2 (Ubiquitin-Conjugating Enzyme E2 D2) is a member of the E2 ubiquitin-conjugating enzyme family, which plays a critical role in the ubiquitin-proteasome system (UPS). This system regulates protein degradation, a fundamental process for maintaining cellular homeostasis, cell cycle progression, DNA repair, and signal transduction. UBE2D2. also known as UBCH5B, facilitates the transfer of ubiquitin molecules to substrate proteins in collaboration with E3 ubiquitin ligases. This post-translational modification typically marks target proteins for proteasomal degradation or modulates their activity, localization, or interactions.
Recombinant UBE2D2 protein is produced in vitro using expression systems like *E. coli* or mammalian cells, enabling controlled studies of its enzymatic activity and interactions. Its structure includes a conserved catalytic core domain (UBC) responsible for binding ubiquitin and coordinating with E3 ligases. Researchers employ recombinant UBE2D2 to dissect ubiquitination mechanisms, screen for inhibitors or activators of the UPS, and model diseases linked to dysregulated protein turnover, such as cancer, neurodegenerative disorders, and immune dysfunctions.
UBE2D2’s broad substrate specificity and interaction with multiple E3 ligases (e.g., MDM2. BRCA1) make it a versatile tool in studying pathways like p53 regulation, NF-κB signaling, and endoplasmic reticulum-associated degradation (ERAD). Aberrant UBE2D2 expression has been implicated in tumor progression and chemotherapy resistance, highlighting its potential as a therapeutic target. However, its ubiquitous expression and functional redundancy with other E2 enzymes (e.g., UBE2D1. D3. D4) pose challenges for selective targeting. Structural and functional insights from recombinant UBE2D2 studies continue to advance drug discovery and mechanistic understanding of ubiquitination in health and disease.
×
